Inhibitor formation in non-severe haemophilia A is a life-long risk and associated with morbidity and mortality. There is a paucity of data to understand real-world inhibitor screening practice. We evaluated the treatment burden, haemostatic strategies, F8 genotyping and inhibitor screening practices in non-severe haemophilia A in seven London haemophilia centres. In the 2-year study period, 44% (377/853) patients received at least one haemostatic treatment. Seventy-nine percent of those treated (296/377) received factor VIII (FVIII) concentrate. F8 genotype was known in 88% (331/377) of individuals. Eighteen per cent (58/331) had 'high-risk' F8 genotypes. In patients with 'standard-risk' F8 genotypes treated on-demand with FVIII concentrate, 51Á3% episodes (243/474) were screened within 1 year. However, poor screening compliance was observed after 'high-risk' treatment episodes. In patients with 'standard-risk' F8 genotypes, 12Á3% (28/227) of treatment episodes were screened in the subsequent 6 weeks after surgery or a bleed requiring ≥5 exposure days. Similarly, in the context of 'high-risk' F8 genotypes after any FVIII exposure, only 13Á6% (12/ 88) of episodes were screened within 6 weeks. Further study is required to assess optimal practice of inhibitor screening in non-severe haemophilia A to inform subsequent clinical decisions and provide more robust prevalence data to further understand the underlying immunological mechanism.
Haemophilia A is a bleeding disorder resulting from an inherited defect in the F8 gene. Severity of haemophilia A is defined by baseline factor VIII (FVIII) coagulant activity (FVIII:C) being either severe (FVIII:C < 1 iu/dl) or nonsevere (FVIII:C 1-40 iu/dl) (Blanchette et al, 2014) . One of the greatest challenges in the management of persons with haemophilia A is the occurrence of FVIII-neutralising antibodies (inhibitors), which occur in 32% of patient with severe haemophilia A (Gouw et al, 2013) . Although the cumulative incidence of inhibitors in non-severe haemophilia A is lower (5Á3%) (Eckhardt et al, 2013) , these antibodies constitute 22% (120/555) of all previously reported inhibitors in the UK (United Kingdom Haemophilia Centres Doctors ' Organisation, 2015) . Clinically, these antibodies in non-severe haemophilia A are of particular concern due to reported cross-reactivity against endogenous FVIII (Hay et al, 1998; Eckhardt et al, 2013) , change in bleeding phenotype (Hay et al, 1998) and increased mortality . In one small study a change in bleeding phenotype and fall in baseline FVIII:C (bFVIII:C) was seen in 22/26 and 24/26 of patients respectively (Hay et al, 1998) . More recently within the INSIGHT study, decrease in bFVIII:C and a change in bleeding phenotype was reported in 34/54 (58%) and 30/54 (51%) of patients respectively (Eckhardt et al, 2013) . In both of these reports however, inhibitor screening was performed only in the context of clinical suspicion of a FVIII inhibitor (change in bleeding phenotype, bFVIII:C or impaired treatment efficacy or FVIII recovery) (Hay et al, 1998; Eckhardt et al, 2013) . Only 11 (19%) of inhibitors were diagnosed on routine screening in asymptomatic patients within the INSIGHT study (Eckhardt et al, 2013) .
Unlike severe haemophilia A, in which FVIII concentrate exposure begins early in life with associated early risk of research paper inhibitor formation [median 14 exposure days (ED)] (Gouw et al, 2007a (Gouw et al, , 2013 and necessity for systematic inhibitor screening (Collins et al, 2013; van den Berg et al, 2016) , treatment in non-severe haemophilia A often commences later in life and is required less frequently. There are often substantial periods of time between treatment episodes and many patients will not receive significant FVIII exposure until later in life, if at all (Den Uijl et al, 2011) . Data from the INSIGHT cohort has suggested a lifelong risk of inhibitor formation in this group of patients (Eckhardt et al, 2013) . However it is not clear when and how to test for FVIII antibodies in non-severe haemophilia A and there is a lack of data to guide these practices. In the UK, consensus guidance stratifies inhibitor screening according to a combination of genetic (F8 genotype) and treatment related factors (FVIII exposure intensity) (Hay et al, 2006; Collins et al, 2013) . There are presently no data describing 'real-world' inhibitor testing practices in patients with non-severe haemophilia A. We report findings from a retrospective audit and evaluation of treatment burden, inhibitor screening and F8 genotyping practices from a large cohort of patients with non-severe haemophilia A treated at haemophilia centres in the London region.
Methods

Case and centre selection
A retrospective chart review was performed of all patients with non-severe haemophilia A treated at all seven London haemophilia centres [four comprehensive care centres (CCC) and three haemophilia treatment centres (HTC)]. All sequentially treated patients with non-severe haemophilia A receiving treatment between 1 January 2011 and 31 December 2012 were included.
The primary objective was to audit inhibitor screening activity against the United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) inhibitor screening guidelines available at the time of study (Hay et al, 2006) . These recommended that patients with moderate and mild haemophilia A receive annual inhibitor screening or after intensive replacement treatment, especially in 'high-risk' F8 mutations. Subsequent UKHCDO guidance has recapitulated these recommendations (Collins et al, 2013) .
The optimal time period in which testing should be performed following such intensive FVIII replacement (so called 'convalescent inhibitor screening') is not defined. For the purpose of this study, convalescent inhibitor screening was defined as testing within 6 weeks (≤42 days) of the first treatment day and categorised for F8 genotype as follows:
'standard-risk' F8 genotype: Annual inhibitor testing in all patients who have received exposure to FVIII concentrate in that year. Follow-up 'convalescent inhibitor screening' after intensive FVIII exposure (≥5 EDs) or surgery.
'high-risk' F8 genotype: Follow up 'convalescent inhibitor screening' after all episodes of exposure to FVIII concentrate.
Secondary objectives were to assess uptake of F8 genotype testing, evaluate treatment patterns [including desmopressin (DDAVP) use], bleeding patterns, timing of inhibitor screening and the incidence of new inhibitors. The study design and data to be collected were discussed with the Clinical Effectiveness Unit (CEU) at The Royal London Hospital and Research Approvals Office (Joint Research Management Office) and represented service evaluation and clinical audit. The study was registered locally at each centre by the lead treating-physician.
Diagnosis and definitions of non-severe haemophilia A All patients were diagnosed locally with bFVIII:C levels derived from the centres' patient registration records. Nonsevere haemophilia A was defined as FVIII:C of 1-50 iu/dl (Hay et al, 1998) . Patients were then further sub-categorised by the investigator as having either moderate (FVIII:C > 1 to ≤5 iu/dl) or mild (FVIII:C > 5 to ≤50 iu/dl) haemophilia A (Hay et al, 1998; White et al, 2001; Blanchette et al, 2014 (Oldenburg & Pavlova, 2006; Astermark et al, 2013) : Arg593Cys (Arg612Cys); Tyr2105Cys (Ty2124Cys); Arg2150His (Arg21-69His); Arg2163His (Arg2182His); Tyr2229Cys (Trp2248Cys); Asn2286Lys (Asn2305Lys) and Pro23000Leu (Pro2319Leu) (Kemball-Cook et al, 1998; Oldenburg & Pavlova, 2006; Astermark et al, 2013) .
Data collection
A standardised data-collection tool was distributed to each of the haemophilia centres, enabling data retrieval directly from electronic patient records (EPR). Data collection took place between 4 April 2013 and 18 June 2013.
Baseline demographic data, including age, bFVIII:C, inhibitor history and F8 genotype result, were collected for all patients. Family history of inhibitor was not available for analysis. Details of all treatment episodes included use of DDAVP and/or FVIII concentrate and/or bypassing agents. For episodes treated with FVIII concentrate, information on treatment indication, timing and results of any subsequent inhibitor testing was requested. Treatment indications were categorised as home-treatment or on-demand (hospital-based Non-Severe Haemophilia A Inhibitor Screening treatment): bleed/trauma; surgery; other; not stated. Surgery was defined as any surgical or dental intervention/procedure requiring haemostatic therapy. An exposure day (ED) was defined as a calendar date in which one or more FVIII infusions was used (Gouw et al, 2007b) . Where treatment episodes did not include FVIII concentrate, no additional information was retrieved. Only hospital-based on-demand episodes and associated inhibitor screens were analysed as these episodes had documented evidence of FVIII being infused. Home-treatment categorised treatment and timing were considered to be too heterogeneous for further analysis.
Assessment of timing of inhibitor testing
Participating haemophilia centre laboratories are accredited by Clinical Pathological Accreditation (CPA) and triennial UKHCDO inspections. Centres performed all inhibitor testing locally and provided dates and results of all inhibitor tests performed within the study period.
For evaluation of annual inhibitor screening, treatment episodes were paired to the nearest subsequent inhibitor test, providing it occurred within 1 year of the first treatment day. For patients who received multiple treatment episodes within a year period, a single inhibitor test could represent an annual inhibitor screen for multiple treatment episodes.
For evaluation of 'paired inhibitor screening', treatment episodes were paired with the nearest subsequent inhibitor test, providing it occurred within 1 year of the first day of treatment and no factor FVIII exposure occurred in the intervening time. If inhibitor testing was not performed within that year or if another treatment episode occurred before an inhibitor screen within the same year, the treatment episode was judged as not having a paired inhibitor screen. If more than one inhibitor test was sent, the treatment episode was paired to the first inhibitor screen with subsequent assays being excluded from the analysis. Consequently, in this sub-analysis, an inhibitor screen could only be paired to a single treatment episode. Screening was assessed as having being sent due to treatment if testing was performed within (AE) 1 day of the subsequent treatment episode. Finally, a true 'convalescent inhibitor screen' was defined as a paired inhibitor screen being performed within 6 weeks after the first day of treatment (≤42 days).
Statistical analyses
Descriptive statistics, including mean, median, standard deviation, inter-quartile range (IQR) and frequency were performed. The annualised bleed rate (ABR) was calculated from the total number of bleeding episodes recorded in the 2-year data collection window, divided by two. Comparative statistics were performed using the Mann-Whitney U and Kruskall-Wallis H tests for continuous and the chi-squared, chi-squared goodness of fit or Fisher's exact test for categorical variables. A post-hoc analysis of factors associated with inhibitor testing was performed by mixed-effects logistic regression for the binary outcome of inhibitor test performed within 6 weeks. All tests performed were two sided, with a P value of <0Á05 taken as being significant. Statistical analyses were performed using either IBM SPSS version 21 (IBM Corp., Armonk, New York, USA), Stata Release 12.1 (StataCorp LP, College Station, TX, USA) or GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla, CA, USA).
Results
A total of 853 persons living with non-severe haemophilia A were registered at the seven haemophilia centres within the London region. Of these, a treatment episode was recorded in 377 (44%) over the 2-year study period [102 (27Á1%) moderate and 275 (72Á9%) mild haemophilia A patients (Table I) ].
Uptake of F8 genotyping
Personal F8 genotype was retrievable in 79% (297/377) of patients who received treatment in the study period. 
Treatment characteristics
Of those receiving haemostatic treatment, 78% (296/377) received FVIII concentrate, with 259 patients (69%) solely receiving FVIII concentrate (Fig 1) . DDAVP was used as part of treatment for 110 patients (29%), with 76 (20%) receiving only DDAVP, 33 (9%) FVIII and DDAVP and 1 (<1%) DDAVP and bypassing agents. DDAVP was used in the management of 10% (10/102) of patients with moderate haemophilia A (DDAVP alone = 4, FVIII and DDAVP = 6) in comparison to 36% (100/275) patients with mild haemophilia A (DDAVP alone = 72, FVIII and DDAVP = 27, DDAVP and bypassing agents = 1). Three patients in whom DDAVP was used had an inhibitor history. An evaluation of the baseline demographics by treatment choices was performed for treatment categories in which there were more than five individuals (FVIII alone, DDAVP alone and FVIII and DDAVP). Patients treated with DDAVP alone were significantly younger (29Á2 years, IQR 14Á6-44Á5) than those treated with FVIII alone (35Á8 years, IQR 16Á6-57Á2, P = 0Á024). Patients treated with DDAVP alone had significantly higher median bFVIII:C (20Á5 iu/dl, IQR 11Á3-29Á0) than those treated with FVIII alone (8Á0 iu/dl, IQR 4Á0-14Á0, P < 0Á0005) or FVIII and DDAVP (10Á0 iu/dl, IQR 7Á0-19Á0, P = 0Á001). No difference in bFVIII:C was seen in those treated with FVIII alone (8Á0 iu/dl IQR 4Á0-14Á0) compared to those treated with FVIII and DDAVP (10Á0 iu/dl, IQR 7Á0-19Á0, P = 0Á0760). A 'whole-case' analysis of the frequency of 'high-risk' F8 genotypes in patients treated with FVIII alone (40/226, 17Á7%), DDAVP alone (9/64, 14Á1%), FVIII and DDAVP (4/32, 12Á5%) did not differ from that expected by chance (P = 0Á642).
On-demand (bleeding and surgery) treatment with FVIII concentrate
Over the study period, 236 patients received FVIII concentrate alone to cover 562 on-demand treatment episodes (surgery = 211, bleeding = 351). Patients received a median of four ED (range 1-159) of FVIII in the 2-year study period (Table I ). These on-demand episodes resulted in a cumulative treatment burden of 2041 ED (bleed = 887 and surgery = 1154).
In the treatment of bleeding, 157 patients received treatment with a FVIII concentrate at hospital to treat a median of one bleeding episode (range 1-15). For surgery, 130 patients received FVIII treatment to cover a median of one surgical episode (range 1-11). Ninety-six patients (32Á4%) were issued FVIII for home treatment, 50 of whom only received home treatment. No further characterisation of home treatment was possible and was thus excluded from further analysis.
Bleeding episodes in non-severe haemophilia A An assessment of bleeding events was performed in a subgroup of 148 patients without a history of inhibitor who only received on-demand FVIII treatment (bleeding or surgery). The median ABR was 0Á5 episodes/year (range 0-4Á5) with 26% of patients having an ABR ≥ 1 (39/148) (Fig 2) .
Inhibitor screening: 'standard-risk' F8 genotype There were 194 'standard-risk' or unknown F8 genotype patients treated with FVIII concentrate for one or more on-demand treatment episode (n = 474) over a cumulative 1753 ED. Of the on-demand treatment episodes, 51Á3% (243/ 474) were followed by an inhibitor screen within 1 year, at a median of 106 days (range 2-365) (Fig 3, Table SI ).
Factor VIII concentrate was used in 175 surgical episodes (106 patients), treated for a median of 1 day (range 1-157). Inhibitor screening was performed within 1 year for 40Á6% (71/175), but only 9Á7% (17/175) of surgical episodes had a true 'convalescent inhibitor screen' performed within 6 weeks of treatment (Fig 3, Table SI ). Of the episodes screened within 6 weeks, 7/17 tests coincided with a subsequent treatment day. Thus only 10/175 (5Á7%) would have a result available to inform the next treatment episode.
There were 299 bleeding episodes (130 patients) treated for a median of 2 days (range 1-75) with FVIII concentrate. Following intensive (≥5 days) FVIII usage for bleeding (n = 39), screening within 6 weeks was performed following 21Á2% (11/52) of these episodes. Two of these 11 coincided with a subsequent treatment day, leaving 9/52 (17Á3%) screened with available results for the next treatment episode.
Inhibitor screening: 'high-risk' F8 genotype
Fifty-eight patients with 'high-risk' F8 genotypes were treated in the study period. Of these, four received home treatment and were excluded and 42 (72%) received one or more ondemand FVIII treatments undergoing 36 surgical episodes and 52 bleeding episodes. Surgical episodes received a median of 1 day (range 1-20) and bleeding episodes a median of 2 days (range 1-19) FVIII treatment.
A paired inhibitor screen was performed following 33Á0% (29/88) of episodes at a median of 93Á5 days (range 2-365) after the first treatment day. Of these episodes, a true 'convalescent inhibitor screen' was performed in only 13Á6% (12/ 88) within 6 weeks of treatment (Fig 3, Table SI ). Of the episodes that received inhibitor screening within 6 weeks, 2/ 12 tests coincided with a subsequent treatment day. Thus, 10/88 (11Á3%) episodes had an inhibitor screen for which the result would be known for the subsequent treatment episode.
Factors influencing convalescent inhibitor screening practises
Multivariate analysis of factors influencing convalescent screening uptake identified imminent treatment (i.e. screened on day of subsequent treatment) as having a strong association, odds ratio (OR) 12Á13 [95% confidence interval (CI) 5Á13-28Á67, P < 0Á001] and treatment episode exposure days a weak association, OR 1Á12 (95% CI 1Á06-1Á19, P < 0Á001). Non-significant variables included: bFVIII:C; reason for treatment; F8 genotype (standard/unknown or high risk) and age (Table SII) .
FVIII inhibitor formation
Thirteen patients had an inhibitor history at the start of the study, with a mean age of 53Á6 years (7Á5-80Á5) and bFVIII: C of 7Á6 iu/dl (1Á9-16Á0). These patients were treated with FVIII alone (n = 5, 38Á5%), DDAVP alone (n = 2, 15Á4%), bypassing agents alone (n = 4, 30Á8%), FVIII and bypassing agents (n = 1, 7Á7%) and DDAVP and bypassing agents (n = 1, 7Á7%). Home-treatment was used for 3/5 patients treated with FVIII alone.
For those without a prior inhibitor history, still at risk of inhibitor formation (n = 290), three developed a new FVIII inhibitor within the study period, detected during treatment for bleeding (n = 2) or upon inhibitor screening (n = 1). A change in the bleeding phenotype was seen in all three patients and fall in bFVIII:C to <1% in two patients. One of these inhibitors was initially only detectable by the inhibitor assay following pre-analytical heat treatment. Two patients had 'high-risk' and one 'standard-risk' F8 genotype. Although all three new inhibitors were detected in a single centre, the total inhibitor frequency for each centre did not differ significantly than that expected by chance (P = 0Á654).
Discussion
Within the London region, nearly half of those living with non-severe haemophilia A (44%, 377/853) received haemostatic treatment within the 2-year study period with a large proportion (79%, n = 296/377) receiving exposure to a FVIII concentrate. For those treated with FVIII concentrate alone (n = 236), this resulted in a cumulative treatment burden for the haemophilia centres of 2041 EDs over 562 treatment episodes and for the patients, an individualised cumulative median treatment burden of four EDs over the 2 years. Our cumulative data identifies a substantial and likely increasing treatment responsibility for haemophilia centres given the ageing haemophilia population and additional co-morbidity risks. This is important to highlight in order to justify appropriate haemophilia centre staffing levels, ensure clear access to specialist care and knowledge of the emergency pathway for this patient group who are probably dependent on the hospital team to administer haemostatic treatment, in contrast to most of those living with severe haemophilia.
The compliance with inhibitor screening in accordance with the available national guidance was generally found to be poor whether judged by the, then current, 2006 or subsequent 2013 UKHCDO guidance (Hay et al, 2006; Collins et al, 2013) . Half of treatment episodes (n = 243, 51Á3%) in patients with 'standard-risk' F8 mutations were followed by an annual inhibitor screen. However, of these patients, only 12Á3% (28/227) were screened within 6 weeks of treatment when indicated by higher treatment intensity or surgery. Similarly, in patients with 'high-risk' F8 genotypes, only 13Á6% (12/88) of episodes were screened within 6 weeks of treatment. Screening was predominantly passive and reactive to subsequent treatment demands (imminent treatment prompting inhibitor screen, OR 12Á13, P < 0Á001) rather than an episode being risk stratified and pro-actively followed up post-exposure.
Testing of F8 genotype and 'high-risk' F8 mutations in non-severe haemophilia A For unbiased assessment of genetic risk of inhibitor formation in non-severe haemophilia A there is a need for high levels of uptake of F8 genotype testing. Within the London haemophilia centres, good uptake of F8 genotype testing was observed (88% known F8 genotype). Marked variation in F8 genotype testing practice has been previously described in an international survey of 13 centres (Gomez & Chitlur, 2013) . Outside of the USA, genetic testing was performed in >75% of cases in 7/8 centres and in the USA, 4/5 centres had performed genetic testing in <50% cases. Similarly, in the recent INSIGHT cohort, the assessment of inhibitor risk associated with F8 genotype could only be performed using data from centres that had genotyped ≥70% of patients, resulting in the exclusion of 59% (20/34) of centres and 1599 patients from the final analysis (Eckhardt et al, 2013) . Risk evaluation of inhibitor formation in such large observational studies is also dependent on adequate laboratory detection of the primary endpoint. Poor compliance with convalescent inhibitor testing, as seen in this London cohort, may significantly impact on data quality within observational studies. This makes interpreting data on inhibitor risk associated with F8 mutations (Eckhardt et al, 2013) and whether patients with inhibitors respond to immunosuppression or subsequent FVIII exposure (van Velzen et al, 2015) difficult due to probable under reporting. Although clinically evident inhibitors (i.e. change in bleeding phenotype) are likely to be detected, those with weaker inhibitory or sub-clinical effect may be missed. However, the totality of immune response to FVIII is vital when trying to understand mechanisms of inhibitor formation and for the development of risk stratification tools.
The selected 'high-risk' F8 genotypes in our evaluation were based on information available within a recently published international study to represent mutations that clinicians may be aware of and could influence inhibitor screening practices. Of these seven 'high-risk' F8 mutations included in the London cohort, four (Arg593Cys, Tyr2105Cys, Arg2150His and Trp2229Cys) have subsequently been described as being associated with increased inhibitor incidence in the INSIGHT study (Eckhardt et al, 2013) . These four F8 mutations accounted for 16% (179/1112) of patients within the INSIGHT study and 57% (29/51) of inhibitor patients had one of these F8 mutations. No inhibitors were seen in the remaining three 'high-risk' F8 mutations in the INSIGHT study although the number of patients with these mutations was low, accounting for only nine patients of the whole cohort (Eckhardt et al, 2013) . All three of these mutations [Arg2163His (Hay et al, 1998; Waseem et al, 1999) , Asn2286Lys (Sharathkumar et al, 2003) and Pro2300Leu (Liu et al, 2000) ] have been described to have been associated with inhibitor formation within the Haemophilia A Database (Kemball-Cook et al, 1998) . The data within the London cohort appears to further support the concept of 'high-risk' F8 genotypes, with these mutations being over-represented (50%, 8/ 16) within the group of patients with an inhibitor. Further study into F8 genotype inhibitor risk is required but potentially limited by difficulty in case-control matching, because some controls will develop inhibitors later in life. Given the number of patients and length of follow-up required, construction of such prospective studies is challenging. In-silico inhibitor risk prediction offers an interesting approach to address some of these difficulties. Work performed by investigators at the Institut national de la sant e et de la recherche m edicale (INSERM) (Pashov et al, 2014) and within our group (Shepherd et al, 2015) have attempted to identify prediction models based around peptide presentation for F8 genotypes at the major histocompatibility complex (MHC) Class II/T-cell receptor interface. These data suggest that risk of inhibitor formation in non-severe haemophilia A is more complex than simple knowledge of the F8 genotype and addition of MHC Class II into clinical prediction algorithms may improve risk prediction.
Timing and methodology of inhibitor testing in nonsevere haemophilia A There is currently no data to guide the optimal timing and methodology for performing inhibitor screening in nonNon-Severe Haemophilia A Inhibitor Screening severe haemophilia A. Within our cohort, inhibitor testing was performed using a functional inhibitor assay, which has limitations in the detection of inhibitors in non-severe haemophilia A due to the likely presence of endogenous FVIII:C in samples. An inhibitor screening test with high specificity (i.e. correctly identifies negative results) and insensitive to residual FVIII:C, such as FVIII enzyme-linked immunosorbent assay (Martin et al, 1999; Sahud et al, 2007; Batty et al, 2015) , or modifications to a functional inhibitor assay, such as pre-analytical heat treatment (Miller et al, 2012; Batty et al, 2014 Batty et al, , 2016 de Lima Montalvao et al, 2015) , may facilitate inhibitor detection in this patient group. A cut-off of ≤6 weeks between treatment event and screening was selected to reflect the likelihood of detecting a primary or anamnestic immunological response and to provide some certainty that screening was intentionally performed following treatment. The FVIII subcommittee of the Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH) has proposed guidance suggesting that all patients with mild haemophilia A have 'convalescent inhibitor screening' using the Bethesda assay six weeks after FVIII exposure (Makris, 2015) . This provides a pragmatic approach for inhibitor screening in an area where there are still many unanswered questions as to what constitutes a 'high-risk' exposure or indeed a 'high-risk' F8 genotype. Inhibitor screening based on a subset of F8 genotypes pre-selected as 'high-risk' may skew toward detection of inhibitors in these groups, particularly if a founder effect is possible. For other F8 genotypes where there is less data, this may lead to false reassurance that other groups of individuals are not at risk of antibody formation and result in lack of detection if these are not screened following treatment. Recently presented data from the INSIGHT case-control study has suggested increased risk of inhibitor development with treatment intensity at first exposure (≥10 ED), any surgical history and higher (>45 iu/dl) peaks of FVIII treatment (van Velzen et al, 2016) . More systematic, pro-active inhibitor screening that does not discriminate by perceived risk of F8 genotype will facilitate the study of both genetic and environmental risks of FVIII antibody formation and allow further characterisation of the immune response to FVIII. Whether these approaches will increase the detection rate of low-titre or transient inhibitors, as recently described in patients with severe haemophilia A (van den Berg et al, 2016) is not clear. Finally, the health economic assessment of increased inhibitor screening should be considered given the substantial associated costs.
DDAVP
The number of patients managed with DDAVP within this cohort was possibly lower than expected. Twenty-nine per cent of patients (110/377) were exposed to DDAVP in the study period, with 1 in 5 (76/377) receiving DDAVP alone for their haemostatic treatment. DDAVP offers a cheap and safe (no inhibitor risk) method of treating responsive patients (without medical contraindication) for minor bleeding or surgery (Srivastava et al, 2013) . There have been varying reports in the literature on factors affecting response to DDAVP which include age, bFVIII:C and F8 genotype (Castaman & Fijnvandraat, 2014) . As expected, patients within our cohort who were treated with DDAVP had higher bFVIII:C levels than those patients treated with FVIII alone. It is possible that the use of DDAVP could further minimise exposure to treatment with FVIII concentrate in responsive patients without medical contraindications (Castaman & Fijnvandraat, 2014) .
Conclusions
Despite nearly half of the individuals in this large cohort receiving haemostatic treatment in the observation period and the causative F8 genotype being known in the majority, we have shown that only a minority undergo targeted inhibitor screening following treatment with FVIII concentrate. This may limit the availability of information valuable to guide future treatment decisions and to inform patients about their future inhibitor risk, whilst also undermining efforts to unpick the underlying immunological mechanisms. Further service development and awareness is required to implement optimal screening practice, timing and methodology of inhibitor screening in patients with non-severe haemophilia A.
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